S-ICD candidacy and limitations: S-ICD is intended for patients who meet standard ICD indications but do not require bradycardia pacing, cardiac resynchronization therapy, or antitachycardia pacing. Limitations include inability to provide pacing/ATP, absence of advanced diagnostics/remote RF interrogation, shorter battery longevity (median first-generation system ~5 years), and higher rates of inappropriate shocks largely due to T-wave oversensing. Reported complications include reintervention (~6.4% within 360 days in EFFORTLESS), inappropriate shocks (~4–16% across studies), pocket infections (reported 1–10% with 1–4% complicated infections), lead migration/dislodgement (3–11%), skin erosion, premature battery depletion, and explantation if pacing/CRT becomes required. Regulatory snapshot: the S-ICD System received FDA PMA approval (P110042) on September 28, 2012.

S-ICD Coverage Considerations summary: S-ICD is covered when the individual meets standard ICD indications and has none of the S-ICD exclusions (no symptomatic bradycardia, no incessant VT, and no spontaneous frequent recurrent VT reliably terminated with ATP). Pre-implant screening is explicitly required with sensing criteria met in ≥1 of 3 leads in 2 different postures (for example supine and sitting or standing); additional disease-specific screening (e.g., stress testing for hypertrophic cardiomyopathy to exclude T-wave oversensing) is recommended. Other listed considerations include avoiding S-ICD use when bradycardia pacing/CRT/ATP is needed, and factoring patient activity, infection/vascular access risk, and device longevity into device selection.

EV-ICD evidence and regulatory summary: The Aurora EV-ICD System (Medtronic) received FDA PMA (P220012) in October 2023 for use with the Epsila EV lead for pacing, cardioversion, and defibrillation in the anterior mediastinum. The pivotal published study by Friedman et al. (2022) was a single-group, nonrandomized premarket trial (n=316 attempted implants) that met its prespecified performance goals: successful defibrillation at implantation (~98.7% with lower CI bound 96.6%) and freedom from major complications at six months (~92.6% with lower CI bound 89.0%); observed limitations included lack of a control group, expert-center implantation, modest spontaneous arrhythmia event counts, limited long-term follow-up, and limited generalizability. Given these evidence limitations, coverage is described as conditional — consideration may be given when patient indications align with approved use and where EV-ICD advantages (extravascular placement with some pacing capability) are relevant, but recognition remains that larger long-term randomized data are needed.

WCD coverage considerations and device limitations: WCD coverage is plan-dependent and, when available, WCDs are medically necessary for high-risk patients who meet ICD criteria but are temporarily unsuitable for implantation (examples: awaiting heart transplant, awaiting reimplantation after infection-related explantation, systemic infection precluding implant) and as a bridge for early post-MI risk stratification (e.g., history of VT/VF after first 48 hours or LVEF ≤35%) or newly diagnosed dilated cardiomyopathy with LVEF ≤35%. WCDs do not provide pacing or ATP. Contraindications/limitations include active ICD presence, age <18 (except for specific FDA pediatric approval), inability/unwillingness to wear device continuously, vision/hearing or medication issues that prevent responding to alarms, pregnancy/breastfeeding per device labeling, and exposure to excessive electromagnetic interference. Pediatric-specific criteria: FDA supplemental approval for certain LifeVest models (2015) permits pediatric use only when chest circumference is ≥ 26 inches (66 cm) and weight is ≥ 41.3 pounds (18.75 kg).

AED considerations and evidence/regulatory summary: All AEDs and AED accessories require FDA PMA. Example PMA: the HeartStart Home Defibrillator (Model M5068A) received PMA (P160029) on June 6, 2019 and is indicated for adults over 55 pounds (25 kg) and for infants/children under 55 lb with optional pads. Randomized and community trials (HAT and PAD) and observational studies show AEDs can terminate VF and are feasible for lay use, with PAD showing improved survival in public access settings; the HAT home AED randomized trial did not demonstrate an overall survival benefit in an intermediate-risk home population despite some survivors who received appropriate shocks. Home AED evidence is therefore limited and does not uniformly support improved overall mortality in residential settings.

Evidence synthesis: Strength of evidence varies by device. S-ICD has moderate observational and registry support (prospective registries, pooled analyses, and systematic reviews) showing high shock efficacy (90–100% for first/final shock), complication-free rates (~30-day ~96%, 1-year ~92.5%), and inappropriate shock rates in the single-digit to mid-teens range; guideline statements endorse S-ICD for selected patients without pacing needs. EV-ICD pivotal data (Friedman 2022) are promising for implant defibrillation success and 6-month safety but are single-group, nonrandomized results with limited long-term and comparative data, and pilot/ASD2 studies show feasibility but small cohorts and short follow-up. WCD support is based mainly on observational registries and consensus guidance for bridging scenarios; randomized data are lacking for many indications. RCTs of AEDs in public-access settings (PAD) show benefit in public locations; the HAT home RCT did not show an overall survival benefit for home AEDs in an intermediate-risk population, highlighting gaps in residential AED effectiveness evidence.